Syndax Pharmaceuticals Inc（SNDX）の株式分析SNDXSyndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Syndax Pharmaceuticals is not a good buy right now due to significant recent setbacks and poor technical indicators. The stock is currently priced at $12.90, down 24.07% over the last 5 days, and has an RSI of 9.59, indicating it is heavily oversold. The failure of the axatilimab trial has led to a sharp decline in investor confidence, and the company's forward P/E ratio is currently at 0, reflecting uncertainty about future earnings. The main risk is the company's high debt-to-equity ratio of 3895.07%, which raises concerns about financial stability.

8 analysts cover SNDX: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 39.11.